drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01284 | DB11003 | 1,042 | 748 | [
"DDInter1782",
"DDInter100"
] | Tetracosactide | Anthrax vaccine | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
1042,
24,
748
]
],
[
[
1042,
25,
676
],
[
676,
63,
748
]
],
[
[
1042,
24,
1683
],
[
1683,
24,
748
]
],
[
[
1042,
64,
1057
],
[
1057,
... | [
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Tetracosactide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
... | Tetracosactide may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ust... |
DB00603 | DB04855 | 303 | 540 | [
"DDInter1137",
"DDInter602"
] | Medroxyprogesterone acetate | Dronedarone | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Moderate | 1 | [
[
[
303,
24,
540
]
],
[
[
303,
6,
8374
],
[
8374,
45,
540
]
],
[
[
303,
21,
28883
],
[
28883,
60,
540
]
],
[
[
303,
24,
473
],
[
473,
... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} ... | Medroxyprogesterone acetate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dronedarone (Compound)
Medroxyprogesterone acetate (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Dronedarone (Compound)
Medroxyprogesterone acetate may cause a moderate interaction that ... |
DB00308 | DB05294 | 347 | 1,069 | [
"DDInter901",
"DDInter1917"
] | Ibutilide | Vandetanib | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
347,
25,
1069
]
],
[
[
347,
21,
28921
],
[
28921,
60,
1069
]
],
[
[
347,
23,
112
],
[
112,
23,
1069
]
],
[
[
347,
24,
659
],
[
659,
... | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Ibutilide",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compou... | Ibutilide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Vandetanib (Compound)
Ibutilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Vandeta... |
DB00227 | DB00250 | 1,463 | 10 | [
"DDInter1098",
"DDInter475"
] | Lovastatin | Dapsone | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | Moderate | 1 | [
[
[
1463,
24,
10
]
],
[
[
1463,
6,
7524
],
[
7524,
45,
10
]
],
[
[
1463,
21,
29462
],
[
29462,
60,
10
]
],
[
[
1463,
24,
478
],
[
478,
... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
]
],
[
[
"Lovastatin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
... | Lovastatin (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Dapsone (Compound)
Lovastatin (Compound) causes Influenza (Side Effect) and Influenza (Side Effect) is caused by Dapsone (Compound)
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib m... |
DB00552 | DB00987 | 1,238 | 1,224 | [
"DDInter1425",
"DDInter461"
] | Pentostatin | Cytarabine (liposomal) | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | Cytarabine can cause developmental toxicity according to an independent committee of scientific and health experts. | Moderate | 1 | [
[
[
1238,
24,
1224
]
],
[
[
1238,
40,
11221
],
[
11221,
1,
1224
]
],
[
[
1238,
1,
903
],
[
903,
40,
1224
]
],
[
[
1238,
5,
11555
],
[
1155... | [
[
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
]
],
[
[
"Pentostatin",
"{u} (Compound) resembles {v} (Compound)",
"Vidarabine"
],
[
"Vidarabine",
"{u} (Compound) resemb... | Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine
Pentostatin (Compound) resembles Vidarabine (Compound) and Vidarabine (Compound) resembles Cytarabine (Compound)
Pentostatin (Compound) resembles Decitabine (Compound) and Decitabine (Compound) resembles Cytarabine (C... |
DB00850 | DB09080 | 1,630 | 144 | [
"DDInter1432",
"DDInter1331"
] | Perphenazine | Olodaterol | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1630,
24,
144
]
],
[
[
1630,
25,
1011
],
[
1011,
24,
144
]
],
[
[
1630,
64,
11
],
[
11,
24,
144
]
],
[
[
1630,
63,
543
],
[
543,
... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Perphenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingol... | Perphenazine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Perphenazine may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate ... |
DB09079 | DB12035 | 1,496 | 943 | [
"DDInter1296",
"DDInter1641"
] | Nintedanib | Sarecycline | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe... | Moderate | 1 | [
[
[
1496,
24,
943
]
],
[
[
1496,
24,
1456
],
[
1456,
24,
943
]
],
[
[
1496,
63,
850
],
[
850,
24,
943
]
],
[
[
1496,
24,
1421
],
[
1421,
... | [
[
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
],
[
... | Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin ... |
DB00331 | DB09156 | 1,645 | 777 | [
"DDInter1164",
"DDInter964"
] | Metformin | Iopromide | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can... | Major | 2 | [
[
[
1645,
25,
777
]
],
[
[
1645,
24,
674
],
[
674,
24,
777
]
],
[
[
1645,
63,
1028
],
[
1028,
24,
777
]
],
[
[
1645,
25,
997
],
[
997,
... | [
[
[
"Metformin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iopromide"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
],
[
"Trich... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Torasemi... |
DB01208 | DB08882 | 945 | 1,281 | [
"DDInter1705",
"DDInter1070"
] | Sparfloxacin | Linagliptin | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
945,
24,
1281
]
],
[
[
945,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
945,
6,
4973
],
[
4973,
45,
1281
]
],
[
[
945,
21,
29081
],
[
29081,
... | [
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
... | Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Sparfloxacin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Linagliptin (Compound)
Sparfloxacin (Compound) causes Angioedema (Side Effect) and An... |
DB00834 | DB06663 | 932 | 1,154 | [
"DDInter1215",
"DDInter1398"
] | Mifepristone | Pasireotide | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
932,
25,
1154
]
],
[
[
932,
63,
966
],
[
966,
40,
1154
]
],
[
[
932,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
932,
23,
112
],
[
112,
... | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
"Octre... | Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide (Compound) resembles Pasireotide (Compound)
Mifepristone (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Mifepristone may cause a min... |
DB00860 | DB00876 | 891 | 1,414 | [
"DDInter1513",
"DDInter658"
] | Prednisolone | Eprosartan | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system. By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced. | Moderate | 1 | [
[
[
891,
24,
1414
]
],
[
[
891,
63,
240
],
[
240,
40,
1414
]
],
[
[
891,
21,
29291
],
[
29291,
60,
1414
]
],
[
[
891,
63,
176
],
[
176,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eprosartan"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Losartan"
],
[
... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Losartan and Losartan (Compound) resembles Eprosartan (Compound)
Prednisolone (Compound) causes Muscular weakness (Side Effect) and Muscular weakness (Side Effect) is caused by Eprosartan (Compound)
Prednisolone may cause a mod... |
DB00382 | DB00863 | 62 | 1,194 | [
"DDInter1734",
"DDInter1568"
] | Tacrine | Ranitidine | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818]... | Moderate | 1 | [
[
[
62,
24,
1194
]
],
[
[
62,
23,
848
],
[
848,
62,
1194
]
],
[
[
62,
24,
1069
],
[
1069,
62,
1194
]
],
[
[
62,
24,
478
],
[
478,
63... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
]
],
[
[
"Tacrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ibuprofen"
],
[
"Ibup... | Tacrine may cause a minor interaction that can limit clinical effects when taken with Ibuprofen and Ibuprofen may cause a minor interaction that can limit clinical effects when taken with Ranitidine
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib and Vandetanib may cau... |
DB06788 | DB09104 | 1,616 | 286 | [
"DDInter864",
"DDInter1118"
] | Histrelin | Magnesium hydroxide | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
1616,
24,
286
]
],
[
[
1616,
63,
820
],
[
820,
23,
286
]
],
[
[
1616,
63,
859
],
[
859,
24,
286
]
],
[
[
1616,
64,
494
],
[
494,
... | [
[
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole a... |
DB00741 | DB13928 | 167 | 1,385 | [
"DDInter885",
"DDInter1660"
] | Hydrocortisone | Semaglutide | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
167,
24,
1385
]
],
[
[
167,
64,
839
],
[
839,
24,
1385
]
],
[
[
167,
24,
637
],
[
637,
24,
1385
]
],
[
[
167,
1,
891
],
[
891,
2... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grepafloxacin"
],
[
... | Hydrocortisone may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia ... |
DB11978 | DB13179 | 124 | 68 | [
"DDInter822",
"DDInter1882"
] | Glasdegib | Troleandomycin | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | A macrolide antibiotic that is similar to erythromycin. | Major | 2 | [
[
[
124,
25,
68
]
],
[
[
124,
63,
1413
],
[
1413,
23,
68
]
],
[
[
124,
23,
466
],
[
466,
23,
68
]
],
[
[
124,
63,
1662
],
[
1662,
24... | [
[
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
]
],
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fexofenadine"
],
[
"Fexofe... | Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Fexofenadine and Fexofenadine may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Glasdegib may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Da... |
DB00635 | DB01197 | 1,573 | 1,603 | [
"DDInter1515",
"DDInter292"
] | Prednisone | Captopril | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Moderate | 1 | [
[
[
1573,
24,
1603
]
],
[
[
1573,
63,
610
],
[
610,
1,
1603
]
],
[
[
1573,
5,
11573
],
[
11573,
44,
1603
]
],
[
[
1573,
6,
1829
],
[
1829,... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
[
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Captopril (Compound)
Prednisone (Compound) treats systemic scleroderma (Disease) and systemic scleroderma (Disease) is treated by Captopril (Compound)
Prednisone (Compound) binds ALB (... |
DB00261 | DB01175 | 702 | 318 | [
"DDInter93",
"DDInter672"
] | Anagrelide | Escitalopram | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Major | 2 | [
[
[
702,
25,
318
]
],
[
[
702,
64,
1230
],
[
1230,
1,
318
]
],
[
[
702,
18,
11048
],
[
11048,
57,
318
]
],
[
[
702,
21,
29276
],
[
29276,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u}... | Anagrelide may lead to a major life threatening interaction when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Anagrelide (Compound) downregulates VAT1 (Gene) and VAT1 (Gene) is downregulated by Escitalopram (Compound)
Anagrelide (Compound) causes Haemoglobin (Side Effect) and Haemog... |
DB00773 | DB01229 | 896 | 973 | [
"DDInter702",
"DDInter1378"
] | Etoposide | Paclitaxel (protein-bound) | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
896,
24,
973
]
],
[
[
896,
24,
310
],
[
310,
63,
973
]
],
[
[
896,
5,
11582
],
[
11582,
44,
973
]
],
[
[
896,
6,
7524
],
[
7524,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Etoposide ... |
DB00912 | DB01359 | 473 | 729 | [
"DDInter1581",
"DDInter1417"
] | Repaglinide | Penbutolol | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Moderate | 1 | [
[
[
473,
24,
729
]
],
[
[
473,
63,
461
],
[
461,
1,
729
]
],
[
[
473,
24,
699
],
[
699,
40,
729
]
],
[
[
473,
21,
28762
],
[
28762,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound)
Repaglinid... |
DB00289 | DB01177 | 847 | 77 | [
"DDInter132",
"DDInter904"
] | Atomoxetine | Idarubicin | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
847,
24,
77
]
],
[
[
847,
6,
12523
],
[
12523,
45,
77
]
],
[
[
847,
18,
1903
],
[
1903,
57,
77
]
],
[
[
847,
21,
28987
],
[
28987,
... | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Atomoxetine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)... | Atomoxetine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Idarubicin (Compound)
Atomoxetine (Compound) downregulates FABP5 (Gene) and FABP5 (Gene) is downregulated by Idarubicin (Compound)
Atomoxetine (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Idarubicin (Compound)
Atomo... |
DB01224 | DB09065 | 623 | 760 | [
"DDInter1553",
"DDInter424"
] | Quetiapine | Cobicistat | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
623,
25,
760
]
],
[
[
623,
64,
1101
],
[
1101,
23,
760
]
],
[
[
623,
24,
1374
],
[
1374,
23,
760
]
],
[
[
623,
63,
723
],
[
723,
... | [
[
[
"Quetiapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Quetiapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} m... | Quetiapine may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause ... |
DB00586 | DB00712 | 1,512 | 1,274 | [
"DDInter537",
"DDInter763"
] | Diclofenac | Flurbiprofen | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Moderate | 1 | [
[
[
1512,
24,
1274
]
],
[
[
1512,
40,
253
],
[
253,
1,
1274
]
],
[
[
1512,
24,
935
],
[
935,
63,
1274
]
],
[
[
1512,
24,
1523
],
[
1523,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Diclofenac",
"{u} (Compound) resembles {v} (Compound)",
"Mefenamic acid"
],
[
"Mefenamic acid",
"{u} (Compound... | Diclofenac (Compound) resembles Mefenamic acid (Compound) and Mefenamic acid (Compound) resembles Flurbiprofen (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with F... |
DB00957 | DB11834 | 873 | 1,303 | [
"DDInter1314",
"DDInter849"
] | Norgestimate | Guselkumab | Norgestimate was first described in the literature in 1977. It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects. It is commonly formulated with [ethinylestradiol] as a combined oral contraceptive that can also be used to treat mod... | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstra... | Moderate | 1 | [
[
[
873,
24,
1303
]
],
[
[
873,
63,
58
],
[
58,
24,
1303
]
],
[
[
873,
40,
1336
],
[
1336,
24,
1303
]
],
[
[
873,
24,
259
],
[
259,
... | [
[
[
"Norgestimate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Norgestimate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[... | Norgestimate may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Norgestimate (Compound) resembles Etonogestrel (Compound) and Etonogestrel may cause a moderate interaction that... |
DB00477 | DB01409 | 216 | 1,415 | [
"DDInter363",
"DDInter1815"
] | Chlorpromazine | Tiotropium | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L... | Moderate | 1 | [
[
[
216,
24,
1415
]
],
[
[
216,
6,
4304
],
[
4304,
45,
1415
]
],
[
[
216,
21,
28779
],
[
28779,
60,
1415
]
],
[
[
216,
23,
752
],
[
752,
... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compo... | Chlorpromazine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Tiotropium (Compound)
Chlorpromazine (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Tiotropium (Compound)
Chlorpromazine may cause a minor interaction that can limit clinical effects when taken with Cimetidine ... |
DB00209 | DB04946 | 352 | 924 | [
"DDInter1886",
"DDInter907"
] | Trospium | Iloperidone | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Moderate | 1 | [
[
[
352,
24,
924
]
],
[
[
352,
24,
1664
],
[
1664,
1,
924
]
],
[
[
352,
24,
519
],
[
519,
40,
924
]
],
[
[
352,
6,
12523
],
[
12523,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles Iloperidone (Compou... |
DB00371 | DB01069 | 1,050 | 401 | [
"DDInter1154",
"DDInter1533"
] | Meprobamate | Promethazine | A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1050,
24,
401
]
],
[
[
1050,
24,
820
],
[
820,
63,
401
]
],
[
[
1050,
24,
104
],
[
104,
24,
401
]
],
[
[
1050,
6,
4973
],
[
4973,
... | [
[
[
"Meprobamate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Meprobamate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Meprobamate may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Meprobamate may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine an... |
DB00909 | DB12130 | 306 | 1,017 | [
"DDInter1971",
"DDInter1094"
] | Zonisamide | Lorlatinib | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
306,
24,
1017
]
],
[
[
306,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
306,
63,
629
],
[
629,
24,
1017
]
],
[
[
306,
24,
214
],
[
214,
... | [
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus... |
DB00704 | DB12141 | 267 | 971 | [
"DDInter1263",
"DDInter817"
] | Naltrexone | Gilteritinib | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
267,
24,
971
]
],
[
[
267,
24,
1135
],
[
1135,
23,
971
]
],
[
[
267,
24,
72
],
[
72,
24,
971
]
],
[
[
267,
63,
847
],
[
847,
24,... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltromb... |
DB09330 | DB10989 | 985 | 496 | [
"DDInter1352",
"DDInter858"
] | Osimertinib | Hepatitis A Vaccine | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
985,
24,
496
]
],
[
[
985,
63,
4
],
[
4,
24,
496
]
],
[
[
985,
24,
738
],
[
738,
63,
496
]
],
[
[
985,
64,
77
],
[
77,
24,
... | [
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepe... | Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Osimertinib may cause a moderate interaction that could exacerbate disea... |
DB00705 | DB05812 | 441 | 1,374 | [
"DDInter496",
"DDInter8"
] | Delavirdine | Abiraterone | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Minor | 0 | [
[
[
441,
23,
1374
]
],
[
[
441,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
441,
21,
28940
],
[
28940,
60,
1374
]
],
[
[
441,
23,
466
],
[
466,... | [
[
[
"Delavirdine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
]
],
[
[
"Delavirdine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)"... | Delavirdine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Delavirdine (Compound) causes Blood alkaline phosphatase increased (Side Effect) and Blood alkaline phosphatase increased (Side Effect) is caused by Abiraterone (Compound)
Delavirdine may cause a minor interaction that can l... |
DB01238 | DB08882 | 673 | 1,281 | [
"DDInter118",
"DDInter1070"
] | Aripiprazole | Linagliptin | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
673,
24,
1281
]
],
[
[
673,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
673,
6,
8374
],
[
8374,
45,
1281
]
],
[
[
673,
21,
28966
],
[
28966,
... | [
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
... | Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Aripiprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Aripiprazole (Compound) causes Upper respiratory tract infec... |
DB00850 | DB12141 | 1,630 | 971 | [
"DDInter1432",
"DDInter817"
] | Perphenazine | Gilteritinib | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
1630,
24,
971
]
],
[
[
1630,
23,
112
],
[
112,
23,
971
]
],
[
[
1630,
63,
485
],
[
485,
24,
971
]
],
[
[
1630,
24,
823
],
[
823,
... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Perphenazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Perphenazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine a... |
DB00497 | DB06663 | 828 | 1,154 | [
"DDInter1366",
"DDInter1398"
] | Oxycodone | Pasireotide | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
828,
24,
1154
]
],
[
[
828,
63,
1314
],
[
1314,
40,
1154
]
],
[
[
828,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
828,
24,
1662
],
[
1662... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desmopressin"
],
[
... | Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Desmopressin (Compound) resembles Pasireotide (Compound)
Oxycodone (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Oxycodone may cause a moderate... |
DB00938 | DB06655 | 455 | 5 | [
"DDInter1635",
"DDInter1077"
] | Salmeterol | Liraglutide | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
455,
24,
5
]
],
[
[
455,
25,
915
],
[
915,
24,
5
]
],
[
[
455,
62,
870
],
[
870,
24,
5
]
],
[
[
455,
63,
245
],
[
245,
24,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Atazanavir"
],
[
"Atazanavi... | Salmeterol may lead to a major life threatening interaction when taken with Atazanavir and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Salmeterol may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone and Fludrocortisone m... |
DB00761 | DB01050 | 1,621 | 848 | [
"DDInter1497",
"DDInter900"
] | Potassium chloride | Ibuprofen | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
1621,
24,
848
]
],
[
[
1621,
21,
28929
],
[
28929,
60,
848
]
],
[
[
1621,
63,
831
],
[
831,
24,
848
]
],
[
[
1621,
64,
240
],
[
240,
... | [
[
[
"Potassium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Potassium chloride",
"{u} (Compound) causes {v} (Side Effect)",
"Confusional state"
],
[
"Confusional state",
... | Potassium chloride (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Ibuprofen (Compound)
Potassium chloride may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin may cause a moderate interaction that could exacerba... |
DB08882 | DB12010 | 1,281 | 214 | [
"DDInter1070",
"DDInter785"
] | Linagliptin | Fostamatinib | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin w... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1281,
24,
214
]
],
[
[
1281,
63,
690
],
[
690,
24,
214
]
],
[
[
1281,
24,
179
],
[
179,
63,
214
]
],
[
[
1281,
24,
1155
],
[
1155,
... | [
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
],
[... | Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl a... |
DB00619 | DB06207 | 1,419 | 910 | [
"DDInter909",
"DDInter1667"
] | Imatinib | Silodosin | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for approximately 75% of α1-adrenocepto... | Moderate | 1 | [
[
[
1419,
24,
910
]
],
[
[
1419,
6,
8374
],
[
8374,
45,
910
]
],
[
[
1419,
21,
28921
],
[
28921,
60,
910
]
],
[
[
1419,
63,
353
],
[
353,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Silodosin"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Imatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Silodosin (Compound)
Imatinib (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Silodosin (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulv... |
DB01238 | DB06663 | 673 | 1,154 | [
"DDInter118",
"DDInter1398"
] | Aripiprazole | Pasireotide | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
673,
24,
1154
]
],
[
[
673,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
673,
62,
112
],
[
112,
23,
1154
]
],
[
[
673,
24,
1385
],
[
1385,
... | [
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Aripiprazole",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side ... | Aripiprazole (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Aripiprazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when t... |
DB00719 | DB08815 | 1,219 | 154 | [
"DDInter149",
"DDInter1104"
] | Azatadine | Lurasidone | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
1219,
24,
154
]
],
[
[
1219,
6,
8374
],
[
8374,
45,
154
]
],
[
[
1219,
24,
1532
],
[
1532,
24,
154
]
],
[
[
1219,
63,
1242
],
[
1242,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Azatadine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Azatadine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lurasidone (Compound)
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone
Azatadine may cause ... |
DB00559 | DB08881 | 152 | 868 | [
"DDInter223",
"DDInter1925"
] | Bosentan | Vemurafenib | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
152,
24,
868
]
],
[
[
152,
6,
8374
],
[
8374,
45,
868
]
],
[
[
152,
21,
29015
],
[
29015,
60,
868
]
],
[
[
152,
62,
608
],
[
608,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Bosentan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Bosentan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Bosentan (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Vemurafenib (Compound)
Bosentan may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidoc... |
DB00957 | DB11767 | 873 | 1,583 | [
"DDInter1314",
"DDInter1643"
] | Norgestimate | Sarilumab | Norgestimate was first described in the literature in 1977. It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects. It is commonly formulated with [ethinylestradiol] as a combined oral contraceptive that can also be used to treat mod... | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Moderate | 1 | [
[
[
873,
24,
1583
]
],
[
[
873,
40,
1336
],
[
1336,
24,
1583
]
],
[
[
873,
24,
1362
],
[
1362,
24,
1583
]
],
[
[
873,
63,
58
],
[
58,
... | [
[
[
"Norgestimate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Norgestimate",
"{u} (Compound) resembles {v} (Compound)",
"Etonogestrel"
],
[
"Etonogestrel",
"{u} may cause a ... | Norgestimate (Compound) resembles Etonogestrel (Compound) and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Norgestimate may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that co... |
DB01268 | DB01591 | 1,151 | 667 | [
"DDInter1731",
"DDInter1696"
] | Sunitinib | Solifenacin | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
1151,
24,
667
]
],
[
[
1151,
6,
8374
],
[
8374,
45,
667
]
],
[
[
1151,
21,
29426
],
[
29426,
60,
667
]
],
[
[
1151,
62,
112
],
[
112,
... | [
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Sunitinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Sunitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Solifenacin (Compound)
Sunitinib (Compound) causes Torsade de pointes (Side Effect) and Torsade de pointes (Side Effect) is caused by Solifenacin (Compound)
Sunitinib may cause a minor interaction that can limit clinical effects when taken with Metr... |
DB06228 | DB11796 | 792 | 1,612 | [
"DDInter1609",
"DDInter786"
] | Rivaroxaban | Fostemsavir | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Moderate | 1 | [
[
[
792,
24,
1612
]
],
[
[
792,
63,
1051
],
[
1051,
23,
1612
]
],
[
[
792,
24,
98
],
[
98,
23,
1612
]
],
[
[
792,
24,
1476
],
[
1476,
... | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
]... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Somatr... |
DB00581 | DB08938 | 355 | 1,384 | [
"DDInter1018",
"DDInter1112"
] | Lactulose | Magaldrate | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Minor | 0 | [
[
[
355,
23,
1384
]
],
[
[
355,
24,
167
],
[
167,
23,
1384
]
],
[
[
355,
63,
251
],
[
251,
23,
1384
]
],
[
[
355,
24,
633
],
[
633,
... | [
[
[
"Lactulose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
... | Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and... |
DB01030 | DB10315 | 869 | 1,137 | [
"DDInter1835",
"DDInter1127"
] | Topotecan | Measles virus vaccine live attenuated | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
869,
25,
1137
]
],
[
[
869,
24,
119
],
[
119,
64,
1137
]
],
[
[
869,
63,
273
],
[
273,
25,
1137
]
],
[
[
869,
64,
581
],
[
581,
... | [
[
[
"Topotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
... | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib and Talazoparib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Tositumom... |
DB09268 | DB14568 | 1,662 | 982 | [
"DDInter1464",
"DDInter1000"
] | Picosulfuric acid | Ivosidenib | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
1662,
24,
982
]
],
[
[
1662,
63,
112
],
[
112,
23,
982
]
],
[
[
1662,
63,
770
],
[
770,
24,
982
]
],
[
[
1662,
63,
472
],
[
472,
... | [
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole... | Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Tha... |
DB00331 | DB00519 | 1,645 | 1,638 | [
"DDInter1164",
"DDInter1843"
] | Metformin | Trandolapril | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiote... | Moderate | 1 | [
[
[
1645,
24,
1638
]
],
[
[
1645,
24,
954
],
[
954,
40,
1638
]
],
[
[
1645,
21,
29305
],
[
29305,
60,
1638
]
],
[
[
1645,
63,
1560
],
[
15... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Trandolapril (Compound)
Metformin (Compound) causes Dysgeusia (Side Effect) and Dysgeusia (Side Effect) is caused by Trandolapril (Compound)
Metformin may cause a moderate interaction t... |
DB00574 | DB00726 | 121 | 1,164 | [
"DDInter717",
"DDInter1876"
] | Fenfluramine | Trimipramine | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Moderate | 1 | [
[
[
121,
24,
1164
]
],
[
[
121,
24,
1237
],
[
1237,
40,
1164
]
],
[
[
121,
25,
939
],
[
939,
40,
1164
]
],
[
[
121,
63,
576
],
[
576,
... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
... | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Trimipramine (Compound)
Fenfluramine may lead to a major life threatening interaction when taken with Benzphetamine and Benzphetamine (Compound) resembles Trimipramine (Compoun... |
DB00586 | DB01105 | 1,512 | 222 | [
"DDInter537",
"DDInter1665"
] | Diclofenac | Sibutramine | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
1512,
24,
222
]
],
[
[
1512,
6,
8374
],
[
8374,
45,
222
]
],
[
[
1512,
21,
29215
],
[
29215,
60,
222
]
],
[
[
1512,
63,
839
],
[
839,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Diclofenac (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Diclofenac (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Sibutramine (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin a... |
DB00472 | DB09104 | 758 | 286 | [
"DDInter758",
"DDInter1118"
] | Fluoxetine | Magnesium hydroxide | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
758,
24,
286
]
],
[
[
758,
24,
820
],
[
820,
23,
286
]
],
[
[
758,
1,
109
],
[
109,
23,
286
]
],
[
[
758,
63,
999
],
[
999,
23,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]... | Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Fluoxetine (Compound) resembles Duloxetine (Compound) and Duloxetine may cause a minor interaction that... |
DB01224 | DB09038 | 623 | 1,450 | [
"DDInter1553",
"DDInter636"
] | Quetiapine | Empagliflozin | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
623,
24,
1450
]
],
[
[
623,
63,
485
],
[
485,
24,
1450
]
],
[
[
623,
24,
659
],
[
659,
63,
1450
]
],
[
[
623,
74,
104
],
[
104,
... | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
... | Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and V... |
DB00685 | DB08880 | 1,299 | 1,510 | [
"DDInter1887",
"DDInter1771"
] | Trovafloxacin | Teriflunomide | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
1299,
25,
1510
]
],
[
[
1299,
24,
1193
],
[
1193,
62,
1510
]
],
[
[
1299,
25,
1144
],
[
1144,
24,
1510
]
],
[
[
1299,
24,
1450
],
[
14... | [
[
[
"Trovafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
],
[
... | Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Trovafloxacin may lead to a major life threatening interaction when taken with Nateglinide and Nateg... |
DB00490 | DB00889 | 946 | 1,133 | [
"DDInter254",
"DDInter840"
] | Buspirone | Granisetron | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic dr... | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Major | 2 | [
[
[
946,
25,
1133
]
],
[
[
946,
6,
8374
],
[
8374,
45,
1133
]
],
[
[
946,
21,
28691
],
[
28691,
60,
1133
]
],
[
[
946,
24,
1213
],
[
1213,... | [
[
[
"Buspirone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
]
],
[
[
"Buspirone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Graniset... | Buspirone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Granisetron (Compound)
Buspirone (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Granisetron (Compound)
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasa... |
DB01377 | DB01403 | 1,283 | 9 | [
"DDInter1119",
"DDInter1175"
] | Magnesium oxide | Methotrimeprazine | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Minor | 0 | [
[
[
1283,
23,
9
]
],
[
[
1283,
62,
1178
],
[
1178,
40,
9
]
],
[
[
1283,
62,
401
],
[
401,
24,
9
]
],
[
[
1283,
62,
1630
],
[
1630,
1... | [
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trifluoperazin... | Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Promethazine and Promethazine may cause a mode... |
DB00280 | DB01176 | 494 | 537 | [
"DDInter575",
"DDInter453"
] | Disopyramide | Cyclizine | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
494,
24,
537
]
],
[
[
494,
24,
1511
],
[
1511,
63,
537
]
],
[
[
494,
40,
11244
],
[
11244,
1,
537
]
],
[
[
494,
24,
104
],
[
104,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Disopyramide (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) resembles Cyclizine (Comp... |
DB06643 | DB12332 | 1,136 | 1,619 | [
"DDInter500",
"DDInter1626"
] | Denosumab | Rucaparib | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1136,
24,
1619
]
],
[
[
1136,
63,
259
],
[
259,
24,
1619
]
],
[
[
1136,
24,
1019
],
[
1019,
24,
1619
]
],
[
[
1136,
24,
1259
],
[
1259... | [
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
... | Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazac... |
DB09420 | DB11166 | 1,074 | 18 | [
"DDInter953",
"DDInter104"
] | Iodide I-123 | Antithrombin Alfa | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Antithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations. | Moderate | 1 | [
[
[
1074,
24,
18
]
],
[
[
1074,
63,
1409
],
[
1409,
25,
18
]
],
[
[
1074,
24,
1421
],
[
1421,
64,
18
]
],
[
[
1074,
63,
1409
],
[
1409,
... | [
[
[
"Iodide I-123",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Antithrombin Alfa"
]
],
[
[
"Iodide I-123",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
],... | Iodide I-123 may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Antithrombin Alfa
Iodide I-123 may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrixaban may... |
DB08880 | DB15035 | 1,510 | 503 | [
"DDInter1771",
"DDInter1959"
] | Teriflunomide | Zanubrutinib | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Major | 2 | [
[
[
1510,
25,
503
]
],
[
[
1510,
25,
868
],
[
868,
24,
503
]
],
[
[
1510,
63,
1430
],
[
1430,
24,
503
]
],
[
[
1510,
64,
1324
],
[
1324,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
... | Teriflunomide may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleuce... |
DB01098 | DB01232 | 14 | 1,327 | [
"DDInter1622",
"DDInter1640"
] | Rosuvastatin | Saquinavir | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Major | 2 | [
[
[
14,
25,
1327
]
],
[
[
14,
25,
833
],
[
833,
1,
1327
]
],
[
[
14,
64,
798
],
[
798,
40,
1327
]
],
[
[
14,
6,
15333
],
[
15333,
45... | [
[
[
"Rosuvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
]
],
[
[
"Rosuvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lopinavir"
],
[
"Lopinavir",
"{u}... | Rosuvastatin may lead to a major life threatening interaction when taken with Lopinavir and Lopinavir (Compound) resembles Saquinavir (Compound)
Rosuvastatin may lead to a major life threatening interaction when taken with Nelfinavir and Nelfinavir (Compound) resembles Saquinavir (Compound)
Rosuvastatin (Compound) bind... |
DB00252 | DB00748 | 362 | 662 | [
"DDInter1460",
"DDInter297"
] | Phenytoin | Carbinoxamine | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
362,
24,
662
]
],
[
[
362,
24,
1594
],
[
1594,
24,
662
]
],
[
[
362,
6,
6017
],
[
6017,
45,
662
]
],
[
[
362,
7,
10670
],
[
10670,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Phenytoin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Carbinoxamine (Compound)
Phenytoin (Com... |
DB00356 | DB08880 | 1,315 | 1,510 | [
"DDInter366",
"DDInter1771"
] | Chlorzoxazone | Teriflunomide | A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202) | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
1315,
25,
1510
]
],
[
[
1315,
24,
850
],
[
850,
25,
1510
]
],
[
[
1315,
63,
1648
],
[
1648,
25,
1510
]
],
[
[
1315,
25,
1377
],
[
1377... | [
[
[
"Chlorzoxazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[... | Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may lead to a major life threatening interaction when taken with Teriflunomide
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleuk... |
DB00197 | DB11979 | 1,324 | 1,320 | [
"DDInter1881",
"DDInter625"
] | Troglitazone | Elagolix | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1324,
24,
1320
]
],
[
[
1324,
63,
168
],
[
168,
23,
1320
]
],
[
[
1324,
23,
608
],
[
608,
23,
1320
]
],
[
[
1324,
24,
1297
],
[
1297,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine... |
DB00081 | DB00939 | 273 | 1,338 | [
"DDInter1838",
"DDInter1135"
] | Tositumomab | Meclofenamic acid | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Major | 2 | [
[
[
273,
25,
1338
]
],
[
[
273,
25,
1479
],
[
1479,
63,
1338
]
],
[
[
273,
24,
384
],
[
384,
63,
1338
]
],
[
[
273,
25,
1347
],
[
1347,
... | [
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetyl... | Tositumomab may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Idelali... |
DB00361 | DB05773 | 134 | 1,047 | [
"DDInter1939",
"DDInter1848"
] | Vinorelbine | Trastuzumab emtansine | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
134,
24,
1047
]
],
[
[
134,
25,
1091
],
[
1091,
24,
1047
]
],
[
[
134,
25,
375
],
[
375,
63,
1047
]
],
[
[
134,
24,
381
],
[
381,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
... | Vinorelbine may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Vinorelbine may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pe... |
DB04951 | DB09122 | 187 | 1,613 | [
"DDInter1477",
"DDInter1409"
] | Pirfenidone | Peginterferon beta-1a | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
187,
24,
1613
]
],
[
[
187,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
187,
63,
600
],
[
600,
24,
1613
]
],
[
[
187,
62,
168
],
[
168,
... | [
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
... | Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Flucon... |
DB00775 | DB10672 | 1,226 | 297 | [
"DDInter1818",
"DDInter417"
] | Tirofiban | Clove | Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. | Clove allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
1226,
23,
297
]
],
[
[
1226,
25,
235
],
[
235,
62,
297
]
],
[
[
1226,
24,
578
],
[
578,
23,
297
]
],
[
[
1226,
25,
1564
],
[
1564,
... | [
[
[
"Tirofiban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Tirofiban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{... | Tirofiban may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a minor interaction that can limit clinical effects when taken with Clove
Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor int... |
DB00661 | DB12141 | 122 | 971 | [
"DDInter1928",
"DDInter817"
] | Verapamil | Gilteritinib | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
122,
24,
971
]
],
[
[
122,
25,
1135
],
[
1135,
23,
971
]
],
[
[
122,
23,
466
],
[
466,
62,
971
]
],
[
[
122,
24,
820
],
[
820,
2... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Verapamil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",... | Verapamil may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Verapamil may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a ... |
DB00757 | DB06788 | 1,166 | 1,616 | [
"DDInter581",
"DDInter864"
] | Dolasetron | Histrelin | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Major | 2 | [
[
[
1166,
25,
1616
]
],
[
[
1166,
23,
112
],
[
112,
23,
1616
]
],
[
[
1166,
64,
1664
],
[
1664,
24,
1616
]
],
[
[
1166,
25,
623
],
[
623,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Dolasetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Dolasetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Dolasetron may lead to a major life threatening interaction when taken with Risperidone and Risperidone may cau... |
DB00582 | DB09122 | 1,622 | 1,613 | [
"DDInter1946",
"DDInter1409"
] | Voriconazole | Peginterferon beta-1a | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
1622,
24,
1613
]
],
[
[
1622,
74,
600
],
[
600,
24,
1613
]
],
[
[
1622,
63,
168
],
[
168,
24,
1613
]
],
[
[
1622,
24,
1274
],
[
1274,
... | [
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Voriconazole",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseas... | Voriconazole (Compound) resembles Fluconazole (Compound) and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Voriconazole may cause a moderate in... |
DB00371 | DB04837 | 1,050 | 649 | [
"DDInter1154",
"DDInter407"
] | Meprobamate | Clofedanol | A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (... | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
1050,
24,
649
]
],
[
[
1050,
24,
1376
],
[
1376,
24,
649
]
],
[
[
1050,
24,
832
],
[
832,
40,
649
]
],
[
[
1050,
63,
701
],
[
701,
... | [
[
[
"Meprobamate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Meprobamate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
... | Meprobamate may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Meprobamate may cause a moderate interaction that could exacerbate diseases when taken with Tripelenn... |
DB00364 | DB09043 | 417 | 135 | [
"DDInter1717",
"DDInter36"
] | Sucralfate | Albiglutide | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
417,
24,
135
]
],
[
[
417,
24,
126
],
[
126,
23,
135
]
],
[
[
417,
63,
1647
],
[
1647,
23,
135
]
],
[
[
417,
23,
624
],
[
624,
2... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
... | Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may ... |
DB00916 | DB01254 | 112 | 1,213 | [
"DDInter1202",
"DDInter484"
] | Metronidazole | Dasatinib | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Minor | 0 | [
[
[
112,
23,
1213
]
],
[
[
112,
6,
8374
],
[
8374,
45,
1213
]
],
[
[
112,
21,
28882
],
[
28882,
60,
1213
]
],
[
[
112,
23,
1247
],
[
1247,... | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dasatinib"
]
],
[
[
"Metronidazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Metronidazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Metronidazole (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Metronidazole may cause a minor interaction that can limit clinical effe... |
DB00377 | DB06595 | 1,494 | 1,491 | [
"DDInter1382",
"DDInter1214"
] | Palonosetron | Midostaurin | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
1494,
24,
1491
]
],
[
[
1494,
23,
112
],
[
112,
23,
1491
]
],
[
[
1494,
24,
888
],
[
888,
24,
1491
]
],
[
[
1494,
24,
657
],
[
657,
... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Palonosetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and ... |
DB00215 | DB06699 | 1,230 | 774 | [
"DDInter388",
"DDInter493"
] | Citalopram | Degarelix | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Major | 2 | [
[
[
1230,
25,
774
]
],
[
[
1230,
64,
521
],
[
521,
1,
774
]
],
[
[
1230,
21,
29232
],
[
29232,
60,
774
]
],
[
[
1230,
23,
112
],
[
112,
... | [
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} (Com... | Citalopram may lead to a major life threatening interaction when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Citalopram (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Citalopram may cause a minor interaction that can limit clinica... |
DB00005 | DB00333 | 1,057 | 576 | [
"DDInter687",
"DDInter1166"
] | Etanercept | Methadone | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Moderate | 1 | [
[
[
1057,
24,
576
]
],
[
[
1057,
24,
494
],
[
494,
40,
576
]
],
[
[
1057,
24,
491
],
[
491,
23,
576
]
],
[
[
1057,
24,
112
],
[
112,
... | [
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
],
[
... | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Methadone (Compound)
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a minor ... |
DB00641 | DB14724 | 467 | 48 | [
"DDInter1675",
"DDInter634"
] | Simvastatin | Emapalumab | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.[A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority... | Moderate | 1 | [
[
[
467,
24,
48
]
],
[
[
467,
74,
1463
],
[
1463,
24,
48
]
],
[
[
467,
64,
376
],
[
376,
24,
48
]
],
[
[
467,
62,
1428
],
[
1428,
24... | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emapalumab"
]
],
[
[
"Simvastatin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken... | Simvastatin (Compound) resembles Lovastatin (Compound) and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Emapalumab
Simvastatin may lead to a major life threatening int... |
DB01118 | DB09122 | 33 | 1,613 | [
"DDInter76",
"DDInter1409"
] | Amiodarone | Peginterferon beta-1a | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
33,
24,
1613
]
],
[
[
33,
64,
600
],
[
600,
24,
1613
]
],
[
[
33,
63,
168
],
[
168,
24,
1613
]
],
[
[
33,
25,
1383
],
[
1383,
63... | [
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
... | Amiodarone may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezom... |
DB00060 | DB14731 | 912 | 1,518 | [
"DDInter947",
"DDInter1741"
] | Interferon beta-1a | Tagraxofusp | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.[A253762, A253887, L43702] Tagraxofusp received its first global approval by t... | Moderate | 1 | [
[
[
912,
24,
1518
]
],
[
[
912,
24,
1324
],
[
1324,
24,
1518
]
],
[
[
912,
24,
242
],
[
242,
63,
1518
]
],
[
[
912,
25,
1070
],
[
1070,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazo... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00539 | DB00682 | 11 | 126 | [
"DDInter1837",
"DDInter1951"
] | Toremifene | Warfarin | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Moderate | 1 | [
[
[
11,
24,
126
]
],
[
[
11,
1,
11234
],
[
11234,
40,
126
]
],
[
[
11,
24,
1335
],
[
1335,
40,
126
]
],
[
[
11,
64,
362
],
[
362,
24... | [
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound)",
"Benzyl Benzoate"
],
[
"Benzyl Benzoate",
"{u} (Compound) ... | Toremifene (Compound) resembles Benzyl Benzoate (Compound) and Benzyl Benzoate (Compound) resembles Warfarin (Compound)
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Warfarin (Compound)
Toremifene may lead to a major life ... |
DB01005 | DB01165 | 995 | 1,539 | [
"DDInter894",
"DDInter1325"
] | Hydroxyurea | Ofloxacin | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Minor | 0 | [
[
[
995,
23,
1539
]
],
[
[
995,
62,
1467
],
[
1467,
1,
1539
]
],
[
[
995,
23,
945
],
[
945,
40,
1539
]
],
[
[
995,
23,
246
],
[
246,
... | [
[
[
"Hydroxyurea",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
]
],
[
[
"Hydroxyurea",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enoxacin"
],
[
"... | Hydroxyurea may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Ofloxacin (Compound)
Hydroxyurea may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Ofloxacin (Compound)
Hydr... |
DB00060 | DB00263 | 912 | 1,029 | [
"DDInter947",
"DDInter1727"
] | Interferon beta-1a | Sulfisoxazole | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms. | Moderate | 1 | [
[
[
912,
24,
1029
]
],
[
[
912,
24,
1247
],
[
1247,
40,
1029
]
],
[
[
912,
24,
161
],
[
161,
1,
1029
]
],
[
[
912,
63,
1560
],
[
1560,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfisoxazole"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamet... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) resembles Sulfisoxazole (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compoun... |
DB04835 | DB14723 | 1,655 | 159 | [
"DDInter1125",
"DDInter1026"
] | Maraviroc | Larotrectinib | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
1655,
24,
159
]
],
[
[
1655,
24,
741
],
[
741,
24,
159
]
],
[
[
1655,
63,
597
],
[
597,
24,
159
]
],
[
[
1655,
64,
1377
],
[
1377,
... | [
[
[
"Maraviroc",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Maraviroc",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
],
[
... | Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and ... |
DB09241 | DB09571 | 1,629 | 1,308 | [
"DDInter1186",
"DDInter1047"
] | Methylene blue | Levmetamfetamine (nasal) | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs ... | Levmetamfetamine is a member of amphetamines. | Moderate | 1 | [
[
[
1629,
24,
1308
]
],
[
[
1629,
63,
1000
],
[
1000,
24,
1053
],
[
1053,
24,
1308
]
],
[
[
1629,
63,
1311
],
[
1311,
63,
1053
],
[
1053,
... | [
[
[
"Methylene blue",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levmetamfetamine"
]
],
[
[
"Methylene blue",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanadrel"
... | Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Levmetamfetamine
Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Guanadrel and Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Procarbaz... |
DB00489 | DB00912 | 17 | 473 | [
"DDInter1704",
"DDInter1581"
] | Sotalol | Repaglinide | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
17,
24,
473
]
],
[
[
17,
21,
28763
],
[
28763,
60,
473
]
],
[
[
17,
25,
609
],
[
609,
63,
473
]
],
[
[
17,
35,
1148
],
[
1148,
6... | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Sotalol",
"{u} (Compound) causes {v} (Side Effect)",
"Chest pain"
],
[
"Chest pain",
"{u} (Side Effect) is caused ... | Sotalol (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Repaglinide (Compound)
Sotalol may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Sotal... |
DB06691 | DB10429 | 849 | 200 | [
"DDInter1155",
"DDInter282"
] | Mepyramine | Candida albicans | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
849,
24,
200
]
],
[
[
849,
63,
701
],
[
701,
24,
200
]
],
[
[
849,
74,
662
],
[
662,
24,
200
]
],
[
[
849,
24,
103
],
[
103,
24,... | [
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
... | Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Mepyramine (Compound) resembles Carbinoxamine (Compound) and Mepyramine may cause a moderate interaction t... |
DB00307 | DB00518 | 1,101 | 510 | [
"DDInter202",
"DDInter35"
] | Bexarotene | Albendazole | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Moderate | 1 | [
[
[
1101,
24,
510
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
510
]
],
[
[
1101,
21,
28680
],
[
28680,
60,
510
]
],
[
[
1101,
24,
1220
],
[
1220... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albendazole"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Albendazole (Compound)
Bexarotene (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Albendazole (Compound)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexametha... |
DB00927 | DB01416 | 1,559 | 1,024 | [
"DDInter712",
"DDInter326"
] | Famotidine | Cefpodoxime | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime. | Moderate | 1 | [
[
[
1559,
24,
1024
]
],
[
[
1559,
24,
665
],
[
665,
40,
1024
]
],
[
[
1559,
24,
1462
],
[
1462,
1,
1024
]
],
[
[
1559,
21,
29243
],
[
2924... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefpodoxime"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
[
... | Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefpodoxime (Compound)
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren and Cefditoren (Compound) resembles Cefpodoxime (Compound... |
DB00781 | DB09156 | 1,481 | 777 | [
"DDInter1489",
"DDInter964"
] | Polymyxin B | Iopromide | Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. All gram-positive bacteria, fungi, and the gram... | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can... | Major | 2 | [
[
[
1481,
25,
777
]
],
[
[
1481,
24,
242
],
[
242,
63,
777
]
],
[
[
1481,
63,
372
],
[
372,
25,
777
]
],
[
[
1481,
25,
1381
],
[
1381,
... | [
[
[
"Polymyxin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iopromide"
]
],
[
[
"Polymyxin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivi... | Polymyxin B may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
Polymyxin B may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clof... |
DB00322 | DB00445 | 141 | 322 | [
"DDInter742",
"DDInter655"
] | Floxuridine | Epirubicin | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Moderate | 1 | [
[
[
141,
24,
322
]
],
[
[
141,
5,
11616
],
[
11616,
44,
322
]
],
[
[
141,
7,
9489
],
[
9489,
46,
322
]
],
[
[
141,
18,
1697
],
[
1697,
... | [
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
]
],
[
[
"Floxuridine",
"{u} (Compound) treats {v} (Disease)",
"stomach cancer"
],
[
"stomach cancer",
"{u} (Disease) is ... | Floxuridine (Compound) treats stomach cancer (Disease) and stomach cancer (Disease) is treated by Epirubicin (Compound)
Floxuridine (Compound) upregulates WIF1 (Gene) and WIF1 (Gene) is upregulated by Epirubicin (Compound)
Floxuridine (Compound) downregulates KPNA2 (Gene) and KPNA2 (Gene) is downregulated by Epirubicin... |
DB09039 | DB12130 | 1,670 | 1,017 | [
"DDInter629",
"DDInter1094"
] | Eliglustat | Lorlatinib | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1670,
24,
1017
]
],
[
[
1670,
64,
271
],
[
271,
23,
1017
]
],
[
[
1670,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
1670,
64,
1554
],
[
1554... | [
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mirabegron"
],
[
"Mirabegron... | Eliglustat may lead to a major life threatening interaction when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a ... |
DB00420 | DB01181 | 508 | 1,532 | [
"DDInter1532",
"DDInter906"
] | Promazine | Ifosfamide | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
508,
24,
1532
]
],
[
[
508,
6,
6017
],
[
6017,
45,
1532
]
],
[
[
508,
63,
1648
],
[
1648,
24,
1532
]
],
[
[
508,
1,
684
],
[
684,
... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Promazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Promazine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Ifosfamide (Compound)
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Promazine (Compoun... |
DB00207 | DB09268 | 1,570 | 1,662 | [
"DDInter157",
"DDInter1464"
] | Azithromycin | Picosulfuric acid | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually tra... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1570,
24,
1662
]
],
[
[
1570,
24,
484
],
[
484,
63,
1662
]
],
[
[
1570,
25,
1618
],
[
1618,
24,
1662
]
],
[
[
1570,
24,
1491
],
[
1491... | [
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
... | Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Azithromycin may lead to a major life threatening interaction when taken with Cabozantinib and Caboza... |
DB00010 | DB01276 | 1,649 | 123 | [
"DDInter1661",
"DDInter706"
] | Sermorelin | Exenatide | Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
1649,
24,
123
]
],
[
[
1649,
24,
1254
],
[
1254,
63,
123
]
],
[
[
1649,
24,
176
],
[
176,
24,
123
]
],
[
[
1649,
24,
1254
],
[
1254,
... | [
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
... | Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin ... |
DB00731 | DB01185 | 1,144 | 155 | [
"DDInter1269",
"DDInter759"
] | Nateglinide | Fluoxymesterone | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women. | Moderate | 1 | [
[
[
1144,
24,
155
]
],
[
[
1144,
24,
1546
],
[
1546,
40,
155
]
],
[
[
1144,
63,
1561
],
[
1561,
40,
155
]
],
[
[
1144,
63,
175
],
[
175,
... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxymesterone"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Fluoxymesterone (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resem... |
DB00595 | DB13909 | 1,545 | 1,277 | [
"DDInter1374",
"DDInter214"
] | Oxytetracycline | Bismuth subgallate | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | Bismuth subgallate is a yellow colored substance that presents as an odorless powder that undergoes discoloration when exposed to sunlight. It is a heavy metal salt of gallic acid that is highly insoluble and poorly absorbed. Possessing protective effects on the gastric mucosa, strong astringent effects, and not as yet... | Moderate | 1 | [
[
[
1545,
24,
1277
]
],
[
[
1545,
40,
964
],
[
964,
24,
1277
]
],
[
[
1545,
40,
964
],
[
964,
40,
1620
],
[
1620,
24,
1277
]
],
[
[
1545,
... | [
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subgallate"
]
],
[
[
"Oxytetracycline",
"{u} (Compound) resembles {v} (Compound)",
"Doxycycline"
],
[
"Doxycycline",
"{u}... | Oxytetracycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subgallate
Oxytetracycline (Compound) resembles Doxycycline (Compound) and Doxycycline (Compound) resembles Tetracycline (Compound) and Tetracycline may cau... |
DB01309 | DB11228 | 1,254 | 721 | [
"DDInter933",
"DDInter1184"
] | Insulin glulisine | Methylcellulose | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Methyl cellulose polymer consisting of numerous linked glucose molecules used as a stabiliser, thickener and emulsifier for foodstuffs and cosmetics. The Degree of Substitution (DS) of a given form of methyl cellulose is defined as the average number of substituted hydroxyl groups per glucose with a theoretical maximum... | Minor | 0 | [
[
[
1254,
23,
721
]
],
[
[
1254,
63,
1411
],
[
1411,
23,
721
]
],
[
[
1254,
63,
1411
],
[
1411,
1,
959
],
[
959,
23,
721
]
],
[
[
1254,
... | [
[
[
"Insulin glulisine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylcellulose"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamid... | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with To... |
DB00015 | DB03404 | 582 | 765 | [
"DDInter1585",
"DDInter855"
] | Reteplase | Hemin | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand. | Moderate | 1 | [
[
[
582,
24,
765
]
],
[
[
582,
25,
840
],
[
840,
63,
765
]
],
[
[
582,
25,
291
],
[
291,
24,
765
]
],
[
[
582,
24,
1018
],
[
1018,
2... | [
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
],
[
"Vorapaxar",
... | Reteplase may lead to a major life threatening interaction when taken with Vorapaxar and Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Reteplase may lead to a major life threatening interaction when taken with Argatroban and Argatroban may cause a moderate interaction t... |
DB00705 | DB06772 | 441 | 310 | [
"DDInter496",
"DDInter259"
] | Delavirdine | Cabazitaxel | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
441,
24,
310
]
],
[
[
441,
25,
973
],
[
973,
24,
310
]
],
[
[
441,
6,
7524
],
[
7524,
45,
310
]
],
[
[
441,
21,
28894
],
[
28894,
... | [
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paclitaxel"
],
[
"Paclita... | Delavirdine may lead to a major life threatening interaction when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Delavirdine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Cabazitaxel (Compound)
Delavirdine (Compound) causes... |
DB00005 | DB00446 | 1,057 | 597 | [
"DDInter687",
"DDInter351"
] | Etanercept | Chloramphenicol | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Moderate | 1 | [
[
[
1057,
24,
597
]
],
[
[
1057,
25,
1101
],
[
1101,
23,
597
]
],
[
[
1057,
25,
450
],
[
450,
62,
597
]
],
[
[
1057,
24,
599
],
[
599,
... | [
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexar... | Etanercept may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Chloramphenicol
Etanercept may lead to a major life threatening interaction when taken with Cyclophosphamide and Cyclophosphamide may cause ... |
DB01193 | DB09564 | 819 | 1,296 | [
"DDInter12",
"DDInter930"
] | Acebutolol | Insulin degludec | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
819,
24,
1296
]
],
[
[
819,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
819,
24,
659
],
[
659,
24,
1296
]
],
[
[
819,
62,
542
],
[
542,
... | [
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
... | Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol an... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.